KRAS and neoplasm: However, due to the susceptibility of patients to develop drug resistance and experience relapse, as well as the ongoing evolution of tumor cells leading to immune evasion, targeted therapies and immunotherapies have shown suboptimal therapeutic efficacy in some patients, especially for patients with KRAS mutation, who account for almost 30% of lung adenocarcinoma cases [5].